A breast cancer treatment from Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) disappointed investors Thursday — leading Nektar stock to topple.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,